Julio A Lamprea-Montealegre1,2,3, Erin Madden2,3, Sri Lekha Tummalapalli2,4, Carmen Peralta1,2,3,5, Torsten B Neilands1,6, Paola K Garcia7, Anthony Muiru1,2, Leah Karliner1,6, Michael G Shlipak1,2,3, Michelle M Estrella1,2,3. 1. Department of Medicine, University of California, San Francisco. 2. Kidney Health Research Collaborative, University of California, San Francisco. 3. San Francisco VA Health Care System, San Francisco, California. 4. Division of Healthcare Delivery Science & Innovation, Department of Population Health Sciences, Weill Cornell Medicine, New York, New York. 5. Cricket Health Inc, San Francisco, California. 6. San Francisco Center for Aging in Diverse Communities and the Multiethnic Health Equity Research Center, University of California, San Francisco. 7. Division of Nephrology, Department of Medicine, Pontificia Universidad Javeriana School of Medicine, Bogotá, Colombia.
Abstract
Importance: Novel therapies for type 2 diabetes can reduce the risk of cardiovascular disease and chronic kidney disease progression. The equitability of these agents' prescription across racial and ethnic groups has not been well-evaluated. Objective: To investigate differences in the prescription of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) among adult patients with type 2 diabetes by racial and ethnic groups. Design, Setting, and Participants: Cross-sectional analysis of data from the US Veterans Health Administration's Corporate Data Warehouse. The sample included adult patients with type 2 diabetes and at least 2 primary care clinic visits from January 1, 2019, to December 31, 2020. Exposures: Self-identified race and self-identified ethnicity. Main Outcomes and Measures: The primary outcomes were prevalent SGLT2i or GLP-1 RA prescription, defined as any active prescription during the study period. Results: Among 1 197 914 patients (mean age, 68 years; 96% men; 1% American Indian or Alaska Native, 2% Asian, Native Hawaiian, or Other Pacific Islander, 20% Black or African American, 71% White, and 7% of Hispanic or Latino ethnicity), 10.7% and 7.7% were prescribed an SGLT2i or a GLP-1 RA, respectively. Prescription rates for SGLT2i and GLP-1 RA, respectively, were 11% and 8.4% among American Indian or Alaska Native patients; 11.8% and 8% among Asian, Native Hawaiian, or Other Pacific Islander patients; 8.8% and 6.1% among Black or African American patients; and 11.3% and 8.2% among White patients, respectively. Prescription rates for SGLT2i and GLP-1 RA, respectively, were 11% and 7.1% among Hispanic or Latino patients and 10.7% and 7.8% among non-Hispanic or Latino patients. After accounting for patient- and system-level factors, all racial groups had significantly lower odds of SGLT2i and GLP-1 RA prescription compared with White patients. Black patients had the lowest odds of prescription compared with White patients (adjusted odds ratio, 0.72 [95% CI, 0.71-0.74] for SGLT2i and 0.64 [95% CI, 0.63-0.66] for GLP-1 RA). Patients of Hispanic or Latino ethnicity had significantly lower odds of prescription (0.90 [95% CI, 0.88-0.93] for SGLT2i and 0.88 [95% CI, 0.85-0.91] for GLP-1 RA) compared with non-Hispanic or Latino patients. Conclusions and Relevance: Among patients with type 2 diabetes in the Veterans Health Administration system during 2019 and 2020, prescription rates of SGLT2i and GLP-1 RA medications were low, and individuals of several different racial groups and those of Hispanic ethnicity had statistically significantly lower odds of receiving prescriptions for these medications compared with individuals of White race and non-Hispanic ethnicity. Further research is needed to understand the mechanisms underlying these differences in rates of prescribing and the potential relationship with differences in clinical outcomes.
Importance: Novel therapies for type 2 diabetes can reduce the risk of cardiovascular disease and chronic kidney disease progression. The equitability of these agents' prescription across racial and ethnic groups has not been well-evaluated. Objective: To investigate differences in the prescription of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) among adult patients with type 2 diabetes by racial and ethnic groups. Design, Setting, and Participants: Cross-sectional analysis of data from the US Veterans Health Administration's Corporate Data Warehouse. The sample included adult patients with type 2 diabetes and at least 2 primary care clinic visits from January 1, 2019, to December 31, 2020. Exposures: Self-identified race and self-identified ethnicity. Main Outcomes and Measures: The primary outcomes were prevalent SGLT2i or GLP-1 RA prescription, defined as any active prescription during the study period. Results: Among 1 197 914 patients (mean age, 68 years; 96% men; 1% American Indian or Alaska Native, 2% Asian, Native Hawaiian, or Other Pacific Islander, 20% Black or African American, 71% White, and 7% of Hispanic or Latino ethnicity), 10.7% and 7.7% were prescribed an SGLT2i or a GLP-1 RA, respectively. Prescription rates for SGLT2i and GLP-1 RA, respectively, were 11% and 8.4% among American Indian or Alaska Native patients; 11.8% and 8% among Asian, Native Hawaiian, or Other Pacific Islander patients; 8.8% and 6.1% among Black or African American patients; and 11.3% and 8.2% among White patients, respectively. Prescription rates for SGLT2i and GLP-1 RA, respectively, were 11% and 7.1% among Hispanic or Latino patients and 10.7% and 7.8% among non-Hispanic or Latino patients. After accounting for patient- and system-level factors, all racial groups had significantly lower odds of SGLT2i and GLP-1 RA prescription compared with White patients. Black patients had the lowest odds of prescription compared with White patients (adjusted odds ratio, 0.72 [95% CI, 0.71-0.74] for SGLT2i and 0.64 [95% CI, 0.63-0.66] for GLP-1 RA). Patients of Hispanic or Latino ethnicity had significantly lower odds of prescription (0.90 [95% CI, 0.88-0.93] for SGLT2i and 0.88 [95% CI, 0.85-0.91] for GLP-1 RA) compared with non-Hispanic or Latino patients. Conclusions and Relevance: Among patients with type 2 diabetes in the Veterans Health Administration system during 2019 and 2020, prescription rates of SGLT2i and GLP-1 RA medications were low, and individuals of several different racial groups and those of Hispanic ethnicity had statistically significantly lower odds of receiving prescriptions for these medications compared with individuals of White race and non-Hispanic ethnicity. Further research is needed to understand the mechanisms underlying these differences in rates of prescribing and the potential relationship with differences in clinical outcomes.
Authors: Abel N Kho; M Geoffrey Hayes; Laura Rasmussen-Torvik; Jennifer A Pacheco; William K Thompson; Loren L Armstrong; Joshua C Denny; Peggy L Peissig; Aaron W Miller; Wei-Qi Wei; Suzette J Bielinski; Christopher G Chute; Cynthia L Leibson; Gail P Jarvik; David R Crosslin; Christopher S Carlson; Katherine M Newton; Wendy A Wolf; Rex L Chisholm; William L Lowe Journal: J Am Med Inform Assoc Date: 2011-11-19 Impact factor: 4.497
Authors: Dhruv Mahtta; David J Ramsey; Michelle T Lee; Liang Chen; Mahmoud Al Rifai; Julia M Akeroyd; Elizabeth M Vaughan; Michael E Matheny; Karla Rodrigues do Espirito Santo; Sankar D Navaneethan; Carl J Lavie; Yochai Birnbaum; Christie M Ballantyne; Laura A Petersen; Salim S Virani Journal: Diabetes Care Date: 2022-02-01 Impact factor: 19.112
Authors: Christopher Cai; Steffie Woolhandler; Danny McCormick; David U Himmelstein; Jessica Himmelstein; Elizabeth Schrier; Samuel L Dickman Journal: J Gen Intern Med Date: 2022-02-09 Impact factor: 6.473
Authors: Lauren A Eberly; Lin Yang; Utibe R Essien; Nwamaka D Eneanya; Howard M Julien; Jing Luo; Ashwin S Nathan; Sameed Ahmed M Khatana; Elias J Dayoub; Alexander C Fanaroff; Jay Giri; Peter W Groeneveld; Srinath Adusumalli Journal: JAMA Health Forum Date: 2021-12-17
Authors: Keith Churchwell; Mitchell S V Elkind; Regina M Benjamin; April P Carson; Edward K Chang; Willie Lawrence; Andrew Mills; Tanya M Odom; Carlos J Rodriguez; Fatima Rodriguez; Eduardo Sanchez; Anjail Z Sharrief; Mario Sims; Olajide Williams Journal: Circulation Date: 2020-11-10 Impact factor: 29.690